Pancreatic Masses
- The pancreas is a quiet organ with a loud reputation: most of its solid masses are adenocarcinoma, and most of those are bad news by the time you see them.
- The first fork in the road is solid vs cystic. Solid usually means cancer until proven otherwise; cystic opens a whole different (often friendlier) menu.
- A solid mass that shows up darker than the rest of the gland after contrast, with an upstream duct ballooning behind it, is the classic adenocarcinoma look.
- The two findings that change everything are vascular involvement (does it hug the arteries and veins?) and distant spread — they decide whether a surgeon can help.
- Pancreatic protocol CT (a timed, two-phase scan) is the workhorse; MRI/MRCP and endoscopic ultrasound back it up.
The pancreas is the shy kid in the back of the abdomen. It sits draped over the spine behind the stomach, makes no fuss, and gives you almost no warning signs — which is exactly why a mass here is so feared. By the time the pancreas raises its hand, it often has something important to say. Let's learn to read it before it shouts.
First fork: is it solid or cystic?
Before you name anything, ask one question: is this thing solid (a chunk of tissue) or cystic (a bag of fluid)? This single split sends you down two completely different hallways.
A solid mass is the scarier hallway. The overwhelming majority of solid pancreatic masses are pancreatic ductal adenocarcinoma — the cancer everyone means when they say "pancreatic cancer." Your default assumption for a new solid mass is adenocarcinoma, and your job is to disprove it, not the other way around.
A cystic lesion is the more hopeful hallway. Many pancreatic cysts are incidental, slow, and either benign or only slowly-on-the-fence. They get worked up carefully, but they don't usually trigger the same alarm bells.
Think of the pancreas like a long branching tree: a central trunk (the main pancreatic duct) with sap flowing through it. A lot of pancreatic disease is really a story about that duct — what blocks it, what balloons it, and what leaks out of it.
The classic villain: ductal adenocarcinoma
Here's the look that should make you sit up. On a contrast-enhanced CT, normal pancreas lights up nicely because it's a vascular gland. Adenocarcinoma is dense, scarry, poorly-vascularized tissue, so it stays relatively dark — a dull region in an otherwise bright gland. Radiologists call it hypoenhancing. In plain English: the tumor is the one part of the gland that refuses to glow.
The second tell is upstream. Most of these tumors grow in the head of the pancreas, right where the main pancreatic duct and the bile duct exit. Block that drainage and everything behind it backs up — the pancreatic duct dilates, the bile duct dilates, and the gland upstream withers. When you see a dilated bile duct and a dilated pancreatic duct both stopping abruptly at the same point, that's the "double duct sign," and it points a finger straight at the pancreatic head. (If the bile duct is involved, this dovetails with gallstones and biliary disease, where painless jaundice is a red flag.)
The two questions a surgeon actually cares about
A surgeon resecting pancreatic cancer doesn't care how poetic the tumor looks. They care about two things, and your report should answer both.
One: does it touch the plumbing? The pancreas is wrapped around major vessels — the superior mesenteric artery and vein, the celiac trunk, the portal vein. The single biggest factor in whether a tumor is operable is how much of these vessels it surrounds. We describe this as the degree of contact (how far around the vessel circumference the tumor wraps). A tumor that just brushes a vessel is very different from one that strangles it.
Two: has it left town? Pancreatic cancer loves to seed the liver and the peritoneum. A tiny liver metastasis can make an otherwise-resectable tumor inoperable, so the liver gets scrutinized hard — this is where overlap with focal liver lesions and LI-RADS thinking helps.
"Resectable," "borderline resectable," and "unresectable" are decided mostly by vessel contact and distant spread — not by tumor size alone. A small tumor choking the SMA can be inoperable; a larger one sitting politely in the tail may not be.
Not everything solid is adenocarcinoma
The pancreas has a few other solid characters worth knowing, because they behave very differently and you don't want to write a death sentence for a curable tumor.
| Mass | Tell-tale look | Why it matters |
|---|---|---|
| Ductal adenocarcinoma | Hypoenhancing, infiltrative, dilates ducts | Most common; usually aggressive |
| Neuroendocrine tumor | Often hyperenhancing (lights up brighter than gland) | Can be slow-growing; very different prognosis |
| Metastasis (e.g., from renal cell) | Can also enhance avidly; known primary | Treat the primary, not as new pancreatic cancer |
| Mass-forming pancreatitis | Inflammation mimicking tumor | Classic mimic — see below |
Inflammation can fake cancer. Focal pancreatitis can form a mass that looks tumor-like, and a tumor can cause obstructive pancreatitis around it — so the two get tangled together. When the imaging is ambiguous, tissue is the tiebreaker, usually via endoscopic ultrasound–guided biopsy.
The cystic hallway, briefly
On the cystic side, the key habit is to describe the cyst precisely: how many compartments, whether it connects to the duct, and whether it has worrisome features like a thickened wall, internal solid nodules, or a duct that's dilated downstream. Those "worrisome features" are what separate a cyst you can watch from one that needs intervention. The exact subtypes are a deeper dive, but the screening instinct is simple: solid components and main-duct dilatation are the things that make me nervous.
How we image it
You can't answer the vessel question on a casual scan. The workhorse is a pancreatic-protocol CT — a timed, multi-phase study where contrast is imaged at the moments when pancreas and vessels are best contrasted. It's a specialized version of the standard abdominal CT approach. MRI with MRCP maps the ducts beautifully and characterizes cysts; endoscopic ultrasound gets close enough to biopsy; and FDG-PET can help hunt for distant disease in selected cases.
If you remember one thing: a dark, infiltrative mass in the pancreatic head with two dilated ducts behind it is adenocarcinoma until proven otherwise — and your report's real value is answering whether it has reached the vessels or left the building.